BONESUPPORT HOLDING AB (SE:BONEX)
:BONEX
Want to see SE:BONEX full AI Analyst Report?
BONEX Stock Chart & Stats
kr184.80
-kr10.40(-2.96%)
At close: 4:00 PM EST
kr184.80
-kr10.40(-2.96%)
Day’s Range― - ―
52-Week Rangekr165.00 - kr346.40
Previous CloseN/A
Volume90.84K
Average Volume (3M)318.62K
Market Cap
kr14.53B
Enterprise Valuekr13.55B
Total Cash (Recent Filing)kr455.26M
Total Debt (Recent Filing)kr14.10M
Price to Earnings (P/E)60.1
Beta0.61
Next Earnings
Jul 09, 2026EPS Estimate
1.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.81
Shares Outstanding65,859,190
10 Day Avg. Volume295,837
30 Day Avg. Volume318,624
Financial Highlights & Ratios
PEG Ratio14.81
Price to Book (P/B)14.28
Price to Sales (P/S)10.54
P/FCF Ratio56.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)4.63
Revenue Forecast (FY)kr1.49B
Bulls Say, Bears Say
Bulls Say
Very High Gross Margins & Operating ProfitabilitySustained gross margins near 95% reflect strong product economics and pricing power for CERAMENT. High margin structure supports scalable operating leverage, funds reinvestment in commercial expansion, and provides a durable buffer against input cost increases and reimbursement variability over the medium term.
Strong Cash Generation & Conservative Balance SheetConsistent positive operating cash flow and a large cash position versus negligible debt give the company financial flexibility to fund U.S. hires, EUROW initiatives, and regulatory timelines without dilution. This cash strength supports durable investment ability and resiliency through reimbursement/regulatory lags.
Robust U.S. Commercial MomentumAccelerating U.S. adoption of CERAMENT G demonstrates product-market fit in the largest orthopedic market. Persistent double-digit constant-currency growth and record sequential increments indicate durable surgeon adoption and distributor traction, underpinning long-term revenue runway and scale benefits.
Bears Say
Regulatory Timing Uncertainty For CERAMENT VUncertain FDA timing for CERAMENT V can delay rollout, NTAP reimbursement eligibility and associated revenue upside. Extended regulatory timelines compress near-term returns on investment and slow clinical adoption, prolonging payback of commercialization spending and delaying structural reimbursement benefits.
Tariff-driven Margin Pressure In U.S.A sustained tariff that trims gross margin by roughly 0.8 p.p. on U.S. business is a structural cost headwind for the highest-growth market. This reduces incremental profitability on expanding sales and forces either price adjustments, margin offsets via efficiency, or slower margin recovery during investment phases.
Historical Cash-flow And Earnings VolatilityRecent cash-generation improvements are encouraging but follow multi-year volatility. Past negative cash flows imply earnings and conversion may deteriorate under stress, meaning long-term sustainability of free cash flow and dividend/return capacity remains contingent on maintaining current growth and margin trends.
BONESUPPORT HOLDING AB News
BONEX FAQ
What was BONESUPPORT HOLDING AB’s price range in the past 12 months?
BONESUPPORT HOLDING AB lowest stock price was kr165.00 and its highest was kr346.40 in the past 12 months.
What is BONESUPPORT HOLDING AB’s market cap?
BONESUPPORT HOLDING AB’s market cap is kr14.53B.
When is BONESUPPORT HOLDING AB’s upcoming earnings report date?
BONESUPPORT HOLDING AB’s upcoming earnings report date is Jul 09, 2026 which is in 68 days.
How were BONESUPPORT HOLDING AB’s earnings last quarter?
BONESUPPORT HOLDING AB released its earnings results on Apr 22, 2026. The company reported kr0.805 earnings per share for the quarter, missing the consensus estimate of kr0.965 by -kr0.16.
Is BONESUPPORT HOLDING AB overvalued?
According to Wall Street analysts BONESUPPORT HOLDING AB’s price is currently Overvalued.
Does BONESUPPORT HOLDING AB pay dividends?
BONESUPPORT HOLDING AB does not currently pay dividends.
What is BONESUPPORT HOLDING AB’s EPS estimate?
BONESUPPORT HOLDING AB’s EPS estimate is 1.11.
How many shares outstanding does BONESUPPORT HOLDING AB have?
BONESUPPORT HOLDING AB has 65,859,190 shares outstanding.
What happened to BONESUPPORT HOLDING AB’s price movement after its last earnings report?
BONESUPPORT HOLDING AB reported an EPS of kr0.805 in its last earnings report, missing expectations of kr0.965. Following the earnings report the stock price went down -1.167%.
Which hedge fund is a major shareholder of BONESUPPORT HOLDING AB?
Currently, no hedge funds are holding shares in SE:BONEX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BONESUPPORT HOLDING AB
Bonesupport Holding AB (publ), an orthobiologics company, develops and commercializes injectable bioceramic bone graft substitutes for the treatment of bone voids in Europe, North America, and internationally. The company provides CERAMENT Bone Void Filler, an injectable, moldable, and drillable synthetic bone void filler that includes hydroxyapatite, calcium sulfate, and the radio-contrast agent iohexol; CERAMENT G, a gentamicin injectable ceramic bone graft substitute; and CERAMENT V, a vancomycin injectable synthetic bone void filler. It also develops preclinical product candidates to promote bone regrowth focusing on trauma, revision arthroplasty, chronic osteomyelitis, revision artroplasty, and oncology, as well as bone and foot infections due to diabetes. The company was founded in 1999 and is headquartered in Lund, Sweden.
BONEX Company Deck
BONEX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a predominantly positive operational picture: strong underlying demand and significant constant-currency revenue growth (notably in the U.S. for CERAMENT G), high gross margins, solid adjusted profitability and robust cash generation. Strategic progress was highlighted by clinical publications, first sales in India, early spine activity, and a favorable CMS proposed ruling that could materially improve reimbursement. Offsetting risks include material currency translation headwinds that reduced reported growth, a tariff-driven margin headwind in the U.S., higher short‑term commercial and incentive costs that will press margins while investments ramp, early-stage/soft BVF spine revenues and timing uncertainty around the CERAMENT V De Novo approval. On balance, the positives (strong growth momentum, cash generation, margin levels, reimbursement progress) materially outweigh the challenges.View all SE:BONEX earnings summariesTechnical Analysis
Options Prices
Currently, No data available
---